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Abstract
Recent studies in prostate tissues and especially cell
lines have suggested roles for arachidonic acid (AA)
metabolizing enzymes in prostate adenocarcinoma
(Pca) development or progression. The goal of this
study was to more fully characterize lipoxygenase
(LOX) and cyclooxygenase-2 (COX-2) gene expression
and AA metabolism in benign and malignant prostate
using snap-frozen tissues obtained intraoperatively
and mRNA analyses and enzyme assays. Formation of
15-hydroxyeicosatetraenoic acid (15-HETE) was de-
tected in 23/29 benign samples and 15-LOX-2 mRNA
was detected in 21/25 benign samples. In pairs of pure
benign and Pca from the same patients, 15-HETE
production and 15-LOX-2 mRNA were reduced in Pca
versus benign in 9/14 (P=.04) and 14/17 (P=.002),
respectively. Under the same conditions, neither 5-
HETE nor 12-HETE formation was detectable in 29
benign and 24 tumor samples; with a more sensitive
assay, traces were detected in some samples, but there
was no clear association with tumor tissue. COX-2
mRNA was detected by nuclease protection assay in 7/
16 benign samples and 5/16 tumors. In benign and
tumor pairs from 10 patients, COX-2 was higher in
tumor versus benign in only 2, with similar results by in
situ hybridization. Paraffin immunoperoxidase for COX-
2 was performed in whole mount sections from 87
additional radical prostatectomy specimens, with
strong expression in ejaculatory duct as a positive
control and corroboration with in situ hybridization. No
immunostaining was detected in benign prostate or
tumor in 45% of cases. Greater immunostaining in tumor
versus benign was present in only 17% of cases, and
correlated with high tumor grade (Gleason score 8 and 9
vs. 5 to 7). In conclusion, reduced 15-LOX-2 expression
and 15-HETE formation is the most characteristic
alteration of AA metabolism in Pca. Increased 12-HETE
and 5-HETE formation in Pca were not discernible.
Increased COX-2 expression is not a typical abnormal-
ity in Pca in general, but occurs in high-grade
tumors. Neoplasia (2001) 3, 287–303.
Keywords: arachidonic acid, eicosanoids, HETEs, 15 - lipoxygenase - 2,
cyclooxygenase.
Introduction
Factors involved in normal growth and differentiation of
the prostate include androgens, stromal— epithelial
interactions, and a variety of polypeptide growth factors
[1–3,4]. Mediators derived from membrane lipids may
also contribute to normal prostate differentiation and
function. Understanding how factors responsible for
normal prostate cellular differentiation are changed in
cancer or how abnormal regulatory pathways are
acquired in malignant cells is crucial to the development
of novel treatment strategies in prostate adenocarcinoma
(PCa). Recent studies have suggested possible roles for
altered arachidonic acid (AA) metabolism in abnormal
growth and differentiation of prostate cancer (Pca) cells
and in tumor cell invasion, metastasis, and stimulation of
angiogenesis. By immunohistochemistry, we have pre-
viously demonstrated the uniform expression of 15-
lipoxygenase-2 (15-LOX-2) in differentiated secretory
cells of benign prostate and reduction of 15-LOX-2 in
most Pcas [5]. Utilizing fresh (not snap) - frozen tissues,
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we have shown that benign prostate synthesized 15-
hydroxyeicosatetraenoic acid (15-HETE) from exogenous
AA and 15-HETE formation was reduced in Pca versus
benign in a small number of pairs of benign and tumor from
the same radical prostatectomy (RP) specimens [5]. A
recent study also showed that reduced 15-LOX-2 immu-
nostaining in tumor correlated with grade, with retention in
most Gleason score 5 tumors (most of which included at
least a component of transition zone Gleason pattern 2
tumor) versus a significant reduction in Gleason score 6
[6]. 15-LOX-2 immunostaining was also reduced in high-
grade prostatic intraepithelial neoplasia compared to benign
glands, suggesting that this may be an early alteration in Pca
development, at least in some cases [6].
Others have reported increased platelet - type 12-LOX
mRNA by semiquantitative RT-PCR in Pca versus benign,
particularly in high-grade, high-stage tumors [7]. Studies in
Pca cell lines have demonstrated a possible role for 12-
HETE in tumor angiogenesis [8 ]. Experiments by other
investigators in cell lines have also suggested a possible role
for 5-LOX in PCa cell proliferation [9–11]. To our knowl-
edge, increased 5- or 12-HETE formation has not been
reported in PCa tissues (as opposed to cell lines). In addition
to these investigations on LOXs, recent studies in cell lines
have also suggested a role for cyclooxygenase-2 (COX-2)
in PCa cell proliferation [12,13]. Prostate cancer is clinically,
genetically, and molecularly heterogeneous [14]. It is crucial
to validate that changes in pathways studied in cell lines
occur in human tumor tissues. The goal of the current study
was to utilize histologically well characterized snap- frozen
prostate tissues, with good RNA and enzyme function
preservation, to further explore the changes in AA metabo-
lism characteristic of PCa.
Materials and Methods
Tissue Procurement, Processing, Histologic
Characterization, and RNA Extraction
Snap- frozen tissues were obtained intraoperatively dur-
ing radical prostatectomy as described previously [15]. Six-
millimeter punch biopsies from multiple transition zone and
peripheral zone sites within the prostate ( right and left, mid to
apex and mid to base) yield cores approximately 1 to 1.5 cm
in length, which are immediately placed in liquid nitrogen.
Cores are correlated with pathology findings in whole mount
processed totally embedded prostates [15]. Pairs of possible
benign and tumor-containing cores from the peripheral zone
of individual patients were retrieved from a maintained
database in the Department of Pathology, The Methodist
Hospital and Baylor College of Medicine, Houston, TX. For
the current study, 60 pairs of these tissues were processed
for RNA and enzyme assays as shown in Figure 1, with
careful correlation to the specific histology of the tissue
actually processed for these analyses. The 1- to 2-mm-
thick transverse section for histology (portion 2 in Figure 1 )
was immediately placed in 10% buffered formalin for routine
processing and paraffin embedding. Cross sections (5-m)
were stained with H&E and assessed for benign, tumor, or
mixed and amount of glands and stroma (both estimated as
percent of tissue section). Greater or equal to 85% benign
was considered benign, greater or equal to 85% tumor was
considered tumor, and all other combinations of benign and
tumor were considered mixed. Grade of tumor was recorded
to verify that it corresponded to the index tumor of the radical
prostatectomy surgical pathology report, and any unique
features of benign glands were noted.
For RNA isolation, 2- to 3-mm transverse slices
(approximately 50 mg) (portion 1 in Figure 1 ) were diced
with fine scissors in 1 ml Tri Reagent (Molecular Research
Center, Cincinnati, OH). Approximately 100 l of auto-
claved 200-m glass beads (BioSpec Products, Bartles-
ville, OK) was added and tissue was further disrupted by
two 20-second periods of agitation on a Mini -Beadbeater
(BioSpec Products), placing the specimen on ice in
between cycles. RNA was then extracted using the Tri
Reagent protocol according to manufacturer’s instructions.
RNA was quantitated by determining optical density at 260
and 280 nm. This procedure generally yielded 50 to 100 g
RNA per sample, which was uniformly intact based on
ethidium bromide stained gels and visualization of riboso-
mal RNA bands.
15-LOX-2 Northern Blots
Twenty micrograms total RNA per sample was electro-
phoresed in 1.2% agarose/ formaldehyde gels and trans-
ferred to Nylon membranes (Nytran SuPerCharge, 0.45-m
pore size, Schleicher and Schuell, Keene, NH). Membranes
were prehybridized for 1 hour at 428C in ULTRAhyb
(Ambion, Austin, TX). Blots were hybridized overnight at
428C with 1106 cpm/ml each of 32P- labeled cDNA probes
for 15-LOX-2 and GAPDH in ULTRAhyb. The 15-LOX-2
probe was a 1088-bp cDNA amplified by PCR from a partial
cDNA in pcDNA3 (Stratagene, La Jolla, CA), with primers
50 -TG-CCT-CTC-GCC-ATC-CAG-CT-30 and 50 -TGG-
GAT-GTC-ATC-TGG-GCC-TGT-30. The GAPDH probe
was a 1100-bp cDNA (Clonetech, Palo Alto, CA). Probes
were labeled by Rediprime II random priming (Amersham,
Arlington Heights, IL). After hybridization, membranes were
washed twice for 5 minutes in 2SSC with 0.05% SDS and
twice for 15 minutes in 0.1SSC with 0.1% SDS. Blots were
Figure 1. Processing of 6 -mm-diameter snap - frozen prostate cores for
RNA extraction, histology, AA incubation enzyme assays, and OCT -
embedded frozen sections.
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exposed to a phosphorimaging screen (Super resolution
screen, Packard Instrument, Meriden, CT) for 1 to 4 hours at
room temperature and imaged on a cyclone storage
phosphor system (Packard) and/or exposed to Kodak X-
OMAT film at 808C for 1 to 3 days. Band intensities were
determined using OptiQuant software ( for phosphorimager)
or by scanning and utilization of NIH Image Analysis software
( for film). The Wilcoxon signed rank test was used to
compare the ratio of 15-LOX-2 band intensity to that of the
housekeeping gene GAPDH in groups of benign and
malignant from the same patients ( run and blotted at the
same time).
COX-2 mRNA Analysis and Immunohistochemistry
COX-2 mRNA expression in benign or tumor-containing
snap- frozen core cross sections (portion 1 in Figure 1 ) was
assessed by nuclease protection assays [16]. The radio-
active riboprobe for COX-2 was a 471-bp fragment from the
30 untranslated region (specific for COX-2 vs. COX-1),
synthesized from 1 g of linearized plasmid using the
MAXIscriptTM kit (Ambion) for 1 hour at 378C in a total
volume of 20 l. The reaction buffer contained 10 mM
dithiothreitol, 0.5 mM ATP, 0.5 mM CTP, 0.5 mM GTP, 2.5
mMUTP, and 5 l of 800 Ci /mmol of [ - 32P]UTP at 10 mCi /
ml. Hybridization was performed with the RPA II kit (Ambion)
with a buffer of 80% deionized formamide, 100 mM sodium
citrate, pH 6.4, and 1 mM EDTA using 10 g total RNA and
5104 cpm labeled COX-2 and beta actin probes for 12
hours at 458C. Subsequent ribonuclease digestion was
performed at 378C for 30 minutes and precipitated, protected
fragments were separated on 4% polyacrylamide gels at 200
V for 3 hours. Gels were exposed to Kodak XAR-5 film
overnight at 808C.
In situ hybridization was performed on formalin - fixed
paraffin embedded sections of the snap- frozen cores
Table 1.







Other ( including seminal vesicle ) 2
TOTAL 60
Benign= >85% benign. Tumor= >85% tumor. Mixed=all other combina-
tions.
Figure 2. Northern blots for 15 -LOX-2 in benign and malignant prostate. Pairs of snap - frozen histologically confirmed pure benign (B ) and pure tumor (T ) from
radical prostatectomy specimens (subset of total cases examined ). Simultaneously probed for housekeeping gene GAPDH. 15 -LOX-2 /GAPDH mRNA ratios
indicated above individual lanes.
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(portion 2 of the cores, processed for histology as in
Figure 1 ) or on formalin - fixed paraffin-embedded sec-
tions cut onto standard-sized charged slides from totally
submitted whole mount processed radical prostatectomy
specimens [5,6 ]. For the former, portions of bladder
tumors previously demonstrated to express COX-2 [16]
were used as positive controls. For the latter, routinely
processed archival specimens, sections from whole
mounts that included portions of the ejaculatory ducts
toward the base of the prostate were used as a positive
control, paralleling the known expression of COX-2 in the
rodent vas deferens [17]. A riboprobe specific for COX-2
versus COX-1 was employed as described [16]. Briefly,
sections were deparaffinized, refixed in paraformaldehyde,
treated with proteinase K (20 g/ml), washed with
phosphate-buffered saline, refixed in 4% paraformalde-
hyde, treated with triethanolamine plus acetic anhydride
(0.25% by volume), and dehydrated with 100% ethanol.
The 471-bp 35S- labeled antisense and sense riboprobes
from the COX-2 specific 30 -untranslated region of the cDNA
were hybridized to the sections for 18 hours at 558C.
Sections were then washed once with 5SSC plus 10 mM
 -mercaptoethanol at 658C, once in 50% formamide in
2SSCwith 100mM  -mercaptoethanol for 30minutes, and
three times in 10 mM Tris, 5 mM EDTA, and 500 mM NaCl
(TEN) at 378C. Sections were subsequently treated with
Rnase A (10 g/ml) at 378C for 30 minutes, followed by
washing once with TEN at 378C and twice in each of 2SSC
and 0.1SSC at 658C. Slides were dehydrated with graded
ethanols with 300 mM ammonium acetate and dipped in
photoemulsion ( Ilford k5, Knutsford, Cheshire, England)
diluted 1:1 with 2% glycerol, and exposed for 4 days at 48C.
Slides were developed in Kodak D-19 and counterstained
with hematoxylin. Slides from the snap- frozen core speci-
mens were reviewed blindly ( including without knowledge of
being parts of benign- tumor pairs ) with a Zeiss Axioskop or
Figure 3. 15 -HETE formation in pairs of snap - frozen histologically confirmed pure benign and pure tumor from radical prostatectomy specimens. Forty - five minute
incubations with 50 M [ 14C ]AA and RP-HPLC analysis with in line radiodetection and simultaneous injection of cold HETE standards. (A ) 15 -HETE formation in
representative benign prostate. (B ) Absent 15 -HETE formation in tumor from same patient as in (A ). (Solvent system for A and B methanol /water / glacial acetic
acid at 80:20:0.01, a flow rate of 1.1 ml /min, with retention time of 15 -HETE approx. 17 minutes ) (C ) Composite results for 14 pairs of pure benign and pure tumor
analyzed. Data are shown as percent of AA converted into 15 -HETE. (D ) Prominent 15 -HETE formation by a high - grade tumor ( cribriform Gleason 4+4=8 ).
(Solvent systemmethanol /water / glacial acetic acid at 85:15:0.01, with retention time of 15 -HETE approx. 10 minutes ). No benign tissue from the same patient was
analyzed. This tumor had prominent 15 - LOX-2 mRNA (not shown ) and also expressed COX-2 mRNA (panel G in Figure 6 ).
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Olympus BX50 microscope using bright - field and dark- field
optics, and areas of benign and tumor on each slide were
assessed as to negative for COX-2, rare positive, focal
( >25%) positive, and diffuse positive. Slides from the whole
mount archival cases that had in situ hybridization performed
on them were compared to the H&E-stained sections, areas
of benign and tumor were mapped on the in situ slides, and
each was assessed for COX-2 expression as above. The
results of these in situ analyses were compared to those for
COX-2 immunostaining on serial sections, using dark- field
and bright - field optics on an Olympus BX50 microscope.
Images were captured using a Nikon D1 digital camera.
In addition to analyses on cross sections of the 6-mm-
diameter snap- frozen cores, immunohistochemistry for
Figure 4. Detection of exogenously added 12 -LOX ( top ) and 5 -LOX (bottom) enzyme activity in prostate homogenates. (A ) 12 -HETE formation from [ 14C ]AA by
purified recombinant human platelet 12 - LOX in 45 -minute incubation in buffer. (B ) RP -HPLC chromatogram of a prostate tumor homogenate incubated for 45
minutes with [ 14C ]AA showing trace formation of 15 -HETE (note different scale compared to A and C). (C ) Identical prostate homogenate as in (B ) with added 12 -
LOX as in (A ), incubated for 45 minutes with [ 14C ]AA, showing prominent formation of 12 -HETE (similar to buffer control ). (D ) Peripheral blood leukocyte extract
incubated in buffer for 45 minutes with [ 14C ]AA, showing expected mixture of 15 -HETE, 12 -HETE, and 5 -HETE. (E ) RP -HPLC chromatogram of a prostate tumor
homogenate incubated for 45 minutes with [ 14C ]AA, showing lack of detectable HETE formation. (F ) Identical prostate homogenate as in (E ) with added leukocyte
extract as in (D ), incubated for 45 minutes with [ 14C ]AA, showing prominent formation of 5 -HETE (as well as 15 - and 12 -HETE ).
Figure 5. COX-2 mRNA in benign and malignant snap - frozen prostate. Nuclease protection assays on pairs of snap - frozen histologically confirmed pure benign
(B ) and pure tumor (T ) from radical prostatectomy specimens ( subset of total cases examined ). Simultaneously analyzed for housekeeping gene  - actin.
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Figure 6. In situ hybridization for COX -2 in sections from benign and malignant snap - frozen prostate tissue. Formalin - fixed paraffin embedded sections of snap -
frozen cores were employed with a riboprobe specific for COX-2. Bright field ( top ) and dark field ( bottom) of identical slide regions. (A ) Expression of COX-2 in
benign prostate. Strong signal in benign gland, with focal negative areas within the gland corresponding to transitional metaplasia ( arrowhead ). (B ) Lack of
detection of COX-2 in tumor ( different case from A). Cribriform high - grade (Gleason pattern 4 ) portion shown (asterisk ). This case was also negative by protection
assays. (C, D ) COX-2 expression in benign prostate (C ) versus lack of COX -2 expression in tumor (D ) from same patient. (E, F ) Focal COX -2 expression in
benign prostate (E ) versus stronger more diffuse expression in high - grade tumor (F ) from same patient. (G ) Strong COX-2 expression in high -grade tumor
(Gleason pattern 4 portion shown ). This tumor also showed strong 15 -LOX-2 expression and formed prominent 15 -HETE and detectable prostaglandins from
exogenous AA. (H ) Lack of detectable COX-2 expression in a different high - grade tumor (Gleason pattern 5 portion shown ). No stronger signal in diffusely
infiltrating tumor ( asterisk ) versus scattered entrapped benign glands ( arrowhead ).
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COX-2 was performed on formalin - fixed paraffin-embed-
ded sections cut onto standard-sized charged slides from
whole mount blocks of 87 totally submitted radical
prostatectomy specimens [5]. Histopathologic analysis of
such cases was performed by a single pathologist
(S.B.S. ) utilizing standard pathologic analysis as
described [6]. Cases were retrieved from a maintained
RP pathology data base at Vanderbilt University Medical
Figure 6. (continued).
Neoplasia . Vol. 3, No. 4, 2001
Arachidonic Acid Metabolism in Prostate Carcinoma Shappell et al. 293
Center Department of Pathology, and sections were
selected to include large portions of the tumor represen-
tative of the overall case and to include ample benign
glands for comparison. Paraffin immunoperoxidase was
performed utilizing a 1:100 dilution of a rabbit anti–COX-
2 polyclonal antibody (160106, Cayman Chemical, Ann
Arbor, MI) on an automated immunostainer (Ventana ES
automated immunohistochemistry system, Ventana Medi-
cal Systems, Tucson, AZ) [5,6 ], employing an avidin–
biotin method with citrate buffer steamer antigen retrieval
using standard techniques. This antibody reacts with
mouse and human COX-2 [16]. In the mouse we have
used portions of the terminal vas deferens (distal end,
toward prostate) as a positive control [17 ], and utilized
similar sections from a COX-2 knockout mouse [18] to
confirm the specificity of the immunostaining (Shappell,
S.B., unpublished observations). In human tissue sec-
tions, we have confirmed the specificity of this antibody by
careful correlation with in situ hybridization for COX-2, as
well as by comparison to immunostaining for COX-1 [16].
In the human studies herein, portions of the ejaculatory
duct at the base of the prostate ( immediately after the
joining of the terminal vas deferens and seminal vesicles)
were used as positive control, with careful correlation to
results of in situ hybridization on serial sections. As
expected from the known expression of COX-2 in vas
deferens and the proximity and similar embryologic origin
of the ejaculatory duct, strong immunostaining and mRNA
expression for COX-2 is obtained in these sections. In
addition to positive controls in each immunoperoxidase
run, more than half of the sections of benign and
malignant prostate from the paraffin-embedded whole
mount blocks studied herein contained cross sections of
the ejaculatory ducts at the various levels of prostate
sections employed, providing an ideal true positive internal
control with which to compare any detected immunostain-
ing in benign and malignant prostate. Eighty-seven radical
prostatectomy cases were immunostained, selected from
our radical prostate data base [5,6] to give a mixture of
different tumor grades, including 14 Gleason score 5, 23
Gleason score 6, 28 Gleason score 7, and 18 Gleason
score 8 [19,20]. Ten cases had histologic features
typical of prior neoadjuvant anti -androgen (Lupron plus
Flutamide or Casodex) treatment [21,22], which was
confirmed by the clinical record. Immunostaining was
considered positive if at least of moderate intensity,
detectable over background with a 10 (and generally
4 ) objective. The extent of COX-2 immunostaining was
assessed in both benign glands and malignant tumor
epithelium from each individual patient and recorded
semiquantitatively as a categorized variable from 0 to
4+, as follows: 0, no detectable immunostaining; 1+, rare
positive cells /glands, less than 5% of the total; 2+, focal
immunostaining involving 5% to 25% glands; 3+, exten-
sive focal, with 25% to 50% glands positive; 4+, greater
that 50% glands (or tumor cells in higher grades)
immunopositive. COX-2 immunostaining in benign and
malignant prostate was compared using the Wilcoxon
signed rank test. To look for a possible effect of grade on
COX-2 expression, samples were grouped into estab-
lished prognostically relevant groups of Gleason score 5
and 6 versus Gleason score 7 versus Gleason score 8
and 9 [20]. Difference scores were computed by taking
the difference in the categorized value of COX-2
expression in the benign versus tumor samples. A chi -
square test of differences for trend based on the
classification of grade was performed. Step-down tests
consisted of performing the Wilcoxon signed rank test
separately by grade.
Arachidonic Acid Incubations and Reverse-Phase HPLC
Analysis
To approximately 50 mg of the snap- frozen cores
(portion 3 in Figure 1 ) four volumes of ice-cold buffer was
added (50 mM Tris, pH 7.4, containing 150 mM NaCl and
100 M CaCl2), and the samples were then diced with fine
scissors, sonicated for 10 seconds using the microprobe of a
Virtis VirSonic 100 at a setting of 5, and further homogenized
on ice using a hand-held Dounce homogenizer designed to
fit an Eppendorf tube. After centrifugation at 5000 rpm for 1
minute in a benchtop centrifuge, the supernatant was
retained and protein concentration determined by the
method of Bradford (Bio-Rad, Hercules, CA). Protein (700
g) of each sample was incubated in 100 l of the same
buffer, begun by addition of 50 M (final concentration) [1-
14C ]AA (New England Nuclear, Boston, MA) in ethanol, with
final solvent concentration less than or equal to 1%. Samples
were incubated for 45 minutes at 378C with continual
agitation and terminated by addition of 2.5 volumes ice-cold
methanol. Lipid extraction and C18 Sep-Pak extraction were
performed as previously described [5]. The extracts were
analyzed by reverse-phase HPLC using a Beckman Ultra-
sphere 5-m ODS column (250.46 cm). Simultaneous
injection of unlabeled 5- , 8- , 9- , 11- , 12- , and 15-HETE
allowed exact determination of retention times of each
HETE. UV spectra and the profiles at 205, 220, 235, and
270 nm were recorded using a Hewlett -Packard 1040A
diode array detector. Radioactivity was generally monitored
with an on- line Radiomatic Instruments Flo-One detector
[5 ]. The usual RP-HPLC assay conditions were injection of
one- fifth of the incubated sample, with a solvent system of
methanol /water /glacial acetic acid at 80:20:0.01 (by vol-
ume) and a flow rate of 1.1 ml /min. This results in a retention
time for 15-HETE of approximately 15 minutes and
adequate resolution of the other HETEs [5]. The Wilcoxon
signed rank test was used to compare the ratio of 15-HETE
formation in groups of benign and malignant from the same
patients ( incubated and run at the same time). In a subset of
benign and tumor pairs, to detect possible low levels of other
HETEs, a solvent system of methanol /water /glacial acetic
acid at 77.5:22.5:0.01 (by volume) was employed at a flow
rate of 1.0 ml /min with collection of 0.5-minute fractions and
10 minutes scintillation counting ( to increase the signal - to-
noise ratio).
Although possible prostaglandin (PG) production may
be suggested by the presence of more polar metabolites
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eluting early in the reverse-phase HPLC run, the above
solvent systems do not allow for adequate separation of
individual cyclooxygenase metabolites, such as PGE2,
from other PGs or other possible polar products not
derived from COX metabolism. In a subset of tumors and
benign- tumor pairs, attention was focused on possible PG
formation using a solvent system of acetonitrile /water /
glacial acetic acid (35:65:0.01, by volume) 0 to 20
minutes, acetonitrile /water /glacial acetic acid (60:40:0.01,
by volume) 20 to 40 minutes, 100% methanol 40 to 60
minutes at 1.1 ml /min, with coinjection of cold TxB2, 6-
keto-PGF1, PGF2, PGE2, PGD2, HHT, 15-HETE, 11-
HETE, 8-HETE, 12-HETE, 9-HETE, and 5-HETE and in-
line radiodetection.
Incubations of exogenous platelet - type 12-LOX and 5-
LOX with prostate homogenates used pure recombinant 12-
LOX (Oxford Biochemicals, Oxford, MI), 2 l of 0.21 mg/ml
enzyme added to 50 l of prostate homogenate, or sonicates
of a human granulocyte/platelet preparation. In each case
the amount of the exogenous source of LOX enzyme(s) was
tested beforehand for activity in buffer alone. An amount
sufficient to give 10% to 20% metabolism of added AA was
then added to fresh prostate homogenates, which were
prepared from an aliquot of frozen tissue that had been
assayed previously for enzyme activity.
Results
Histologic Examination of Snap-Frozen Prostate Samples
Snap- frozen prostate tissues were obtained intraoper-
atively using 6-mm punch biopsies as described [15]. In 60
patients, two of the eight cores collected from each prostate
were selected as benign or tumor based on correlation with
the pathology in whole mount sections [15]. These cores
were processed for RNA, formalin fixation and paraffin
embedding, and AA incubation enzyme assays as shown in
Figure 1. The length of each biopsy processed for the studies
reported herein was approximately 5 mm, or roughly the
thickness of tissue submitted for routine light microscopic
sections. The histology of the middle portion was thus taken
as indicative of tissue processed for RNA and enzyme
assays. The results of histologic examination of the pairs of
tissues utilized are summarized in Table 1. A total of 22 of the
60 pairs were composed of pure benign and pure tumor from
individual patients. Other benign, tumor, and mixed tissues
were also utilized as indicated in the results below.
15-LOX-2 Expression in Benign and Malignant Prostate
By Northern analysis, 15-LOX-2 mRNA was detected in
21/25 benign samples. In 17 pairs of pure benign and Pca
from the same patient, 15-LOX-2 mRNA was detected in
15/17 benign samples and 12/17 tumor samples. 15-LOX-
2 mRNA (normalized to GAPDH) was significantly reduced
in tumor versus benign (P=.002), with 14/17 pairs having
reduced 15-LOX-2 levels in tumor, two pairs in which 15-
LOX-2 was not detected in either benign or malignant, and
one case with higher 15-LOX-2 in tumor (Figure 2 ). In the
14 pairs in which message was reduced in tumor, 15-LOX-2
mRNA was present in benign but not detectable in tumor in
three. In the other 11, 15-LOX-2 mRNA was an average of
5.3- fold higher in benign ( range 1.02- to 17.8- fold).
15-HETE Formation in Benign and Malignant Prostate
In the snap- frozen cores, 15-HETE formation from
exogenous AA was detected in 23/29 incubations of benign
prostate from 26 patients ( including those in which paired
benign and tumor tissues were incubated, as described
below). As observed previously with fresh (not snap)- frozen
prostate, 15-HETE was the major AA metabolite formed
under these conditions. In the positive benign incubations,
the conversion of 50 M exogenous AA to 15-HETE was
2.95±2.95% (mean±SD; range 0.74% to 11.8%). 15-HETE
formation was also detected in incubations of 6/6 samples of
mixed benign and tumor; the percent conversion of
exogenous AA in these mixed samples was 3.16±5.12%
(mean±SD; range 0.61% to 13.5%). 15-HETE formation
was detected in only 1/4 pure tumors in which benign tissue
was not available from the same patient. Of the six negative
benign samples, one had transitional metaplasia and one
had atrophy, conditions known to be negative for 15-LOX-2
by immunohistochemistry [5 ]. Three of the other four were
composed predominantly (greater than half ) of stroma, also
known to be negative for 15-LOX-2 [5]. The one positive
pure tumor (without a paired benign sample) had particularly
prominent 15-HETE formation (14.8% conversion). This
level of catalytic activity was even greater than that in benign
samples in the current series. This tumor also had prominent
15-LOX-2 mRNA expression (not shown). Histologically,
this tumor was composed of cribriform Gleason pattern 4
Table 2. Correlation of COX-2 mRNA and Enzyme Activity in Select Snap -Frozen Samples.
Tissue Histology* COX Activity (PGE /HHT) COX-2 mRNA Protection Assay COX-2 mRNA In Situ Hybrid
Benign — patient 1 Positive Negative Negative
Tumor — patient 1 Negative Negative Positive ( diffuse glands )
Benign — patient 2 Negative Negative N /Dy
Tumor — patient 2 Positive Negative Positive ( rare glands )
Tumor — patient 3 Positive Positive Positive ( diffuse glands )
Tumor — patient 4 Positive Positive Positive ( focal glands )
Tumor — patient 5 Negative Negative ± ( rare glands )
*Patient numbers are arbitrary, to indicate paired samples, and do not correlate with numbers in Figure 2.
yN/D=not determined.
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Figure 7. Immunohistochemistry and in situ hybridization for COX -2 in benign and malignant prostate from paraffin -embedded whole mount sections. (A ) Strong
COX-2 immunostaining in epithelium in portion of ejaculatory duct cross section from base of prostate ( top left ), with adjacent negative benign glands ( right ). (B ) In
situ hybridization showing strong COX-2 mRNA expression in similar portion of ejaculatory duct in serial section from same specimen as (A ). Benign glands at right
negative. (C ) Strong COX-2 immunostaining in seminal vesicle epithelium ( top ), with negative high - grade carcinoma (middle and bottom) in base of prostate. (D )
In situ hybridization of serial section from same specimen as in (C ), showing strong uniform COX-2 mRNA expression in seminal vesicle, with negative prostate
carcinoma below. (E ) ) Focal strong COX-2 immunostaining in benign glands from central zone of prostate. ( F ) Heterogeneous COX-2 immunostaining in a
positive high - grade carcinoma case. Left, negative immunostaining in focus of cribriform Gleason pattern 4 carcinoma; middle, positive COX -2 immunostaining in
another region of cribriform Gleason pattern 4 carcinoma; right, positive COX-2 immunostaining in focus of carcinoma with ductal morphology (prostatic ductal
carcinoma ) from same patient. (G ) Positive COX -2 immunostaining in focus of high - grade carcinoma, including infiltrating single tumor cells, in patient with
Gleason score 4+5=9 tumor, with negative stroma and lymphoid aggregate in bottom right. (H ) Diffuse grains of positive COX -2 in situ hybridization over same
area of cellular high - grade tumor in serial section from specimen in (G ), with similarly negative lymphoid aggregate, bottom right. ( I, J ) COX-2 immunostaining in
distinct foci of different grade tumor from same patient, with negative Gleason pattern 2 from Gleason score 2+3=5 tumor largely in transition zone ( I ) and strong
immunostaining in foci of COX-2 positive Gleason score 4+5=9 tumor in peripheral zone ( J ).
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(Gleason score 4+4=8). Several tumors with this morphol-
ogy have been previously observed to have positive 15-
LOX-2 immunostaining in contrast to the usual reduction or
loss of 15-LOX-2 immunostaining in Pca [6].
In pairs of pure benign and Pca from the same patient, 15-
HETE production from AA was present in 9 of 14 benign
samples and 5 of 14 tumor samples. The mean±SD for
percent AA conversion was 2.79±3.7% for benign and
0.37±0.60% for tumor, considering all 14 cases. 15-HETE
formation was significantly reduced in tumor versus benign
(P=.04), with 9/14 pairs having reduced 15-HETE in tumor,
three pairs with 15-HETE detected in tumor but not benign,
and two pairs for which 15-HETE was not detected in either
(Figure 3 ). Of the nine pairs for which 15-HETEwas reduced
in tumor, seven also had reduced 15-LOX-2mRNA. (No 15-
LOX-2 mRNA was detected in benign or tumor in one pair;
Northern data was not generated in one pair. ) For the two
pairs in which 15-HETE was not detected in either benign or
tumor, Northern blot data for 15-LOX-2 was not generated
for one, and only faint 15-LOX-2 mRNA was detected in the
other pair (benign>malignant). For the three pairs in which
15-HETEwas detected in tumor but not benign, one found no
15-LOX-2 mRNA in benign or tumor, one had increased 15-
LOX-2 mRNA in benign, and no Northern data was
generated for the third. The data as presented is not adjusted
for glandular content of the incubated specimen. As 15-
LOX-2 is present in benign glands and in malignant
epithelium in those tumors that are 15-LOX-2 positive [5 ]
and stroma may contribute to the total amount of protein
incubated per sample, the differences between benign and
tumor may be even more pronounced as the gland content is
generally higher in the tumor portions (greater gland content
in tumor versus benign in 13/14 incubated pairs; essentially
equal in 1/14; not shown). Whereas several negative benign
samples were composed predominantly ( >50%) of stroma,
all of the incubated tumors were composed predominantly
(greater than one half ) of glandular epithelium.
Analysis of Possible 5- and 12-LOX Activity in Benign and
Malignant Prostate
The methodology employed in the tissue incubations
allows for the simultaneous detection of other AA metabo-
lites besides 15-HETE. Under assay conditions in which 15-
HETE production is readily apparent in the majority of benign
prostate incubations, there was no detectable 5-HETE or
12-HETE production in benign prostates (n=29). The
Figure 7. (continued).
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reports suggesting possible increased platelet - type 12-LOX
in Pcas have shown a correlation with high tumor grade [7]
and most of the data suggesting a potential role for 5- and
12-LOX has been generated in cancer cell lines, which are
established from high-grade/advanced tumors. Hence we
anticipated the possible production of these metabolites
primarily in tumor incubations, and therefore we included a
number of higher grade tumors in the analyses (Gleason
grade 7). Under the usual HPLC conditions ( injection of
one- fifth of incubation extracts) in which 15-HETE is readily
detectable in benign prostate, neither 5-HETE nor 12-HETE
production were detected in any of 24 tumor AA incubations
(6 mixed benign and tumor, 18 pure tumor).
To examine the samples for possible low levels of 5-
HETE or 12-HETE, we reanalyzed a subset of the same
samples ( five benign- tumor pairs and three additional
tumors) by injection of the remaining four - fifths of the
incubation extracts. The tumor samples included one each of
Gleason score 5, 6, and 7, and five of Gleason score 8. Trace
levels of 5-HETE ( <0.25% AA conversion) were formed in
two of five benign and two of eight tumor samples. Trace
levels of 12-HETE ( <0.5% AA conversion) were detected in
one of five benign and two of eight tumor samples. In paired
samples, there was no indication of increased 5-HETE or
12-HETE in tumor versus benign.
To be certain that our assay conditions were adequate to
detect 5-and 12-HETE formation and that no inhibiting
effect of the prostate homogenates was present, prostate
homogenates negative for 5- and 12-HETE production were
incubated with purified recombinant human platelet - type
12-LOX and with leukocyte extracts as a source of 5-LOX.
As shown in Figure 4, these positive controls showed 12-
and 5-HETE formation, overall similar in magnitude to buffer
incubations without prostate homogenate ( >75% equivalent
peak heights in spiked prostate homogenates compared to
control buffer ). These results confirm the ability to detect 5-
and 12-HETE formation when enzyme activity is present
and show that prostate homogenates have any necessary
cofactors for enzyme activity and do not possess inhibiting
substances for these LOX enzymes.
COX-2 mRNA in Benign and Malignant Prostate in Snap-
Frozen Tissues
COX-2 mRNA analysis by multiple methods in snap-
frozen core portions showed no consistent difference
between benign peripheral zone prostate and Pca. COX-2
mRNA was detected by Rnase protection assays in 7/16
benign and 5/16 tumor samples. In benign and tumor pairs
from 10 patients, COX-2 was negative in both in 5; positive
in benign/negative in tumor in 3; negative in benign/positive
in tumor in 2 (Figure 5 ).
In situ hybridization for COX-2 mRNA was performed on
formalin- fixed paraffin-embedded portions of 32 snap-
frozen samples (15 benign and 17 tumor samples, including
paired benign and tumor from 10 patients). COX-2 mRNA
expression was detected in both glands and, to a lesser
extent, in stroma ( including vessels) of benign andmalignant
prostate. Similar to the protection assays, however, there
was no discernable consistent difference in COX-2 expres-
sion between benign and malignant prostate. Of 15 benign
prostate samples, 8 showed at least focal ( >25%) expres-
sion in epithelium of benign glands (Figure 6 ); 3 showed only
rare (approximately 5%) positive glands, and 4 were
negative. Of 17 tumor samples, 7 showed at least focal
( >25%) COX-2 expression in malignant epithelium, 7
showed only rare or scattered epithelial expression, and 3
were negative (Figure 6 ). A subset of positive samples
probed with a sense-strand control were completely
negative (not shown). In 10 pairs of benign and tumor, 5 /
10 showed essentially similar levels of expression in both
benign and malignant, 3 /10 showed a greater degree of
expression in benign versus tumor, and only 2/10 showed
greater expression in tumor versus benign (Figure 6 ).
Correlation of COX-2 Expression and PG Formation in
Snap-Frozen Tissues
PG production was not generally conspicuous in benign
and tumor samples under our usual HPLC conditions. In a
subset of cases subjected to an expanded HPLC analysis of
a greater sample volume, trace PGE2 formation ( <0.25%AA
conversion) and hydroxyheptadecatrienoic acid (HHT)
formation ( <0.5% AA conversion) were detected in two of
three separate tumors, in one tumor of a benign- tumor
(Gleason score 7) pair ( <0.5% AA conversion) and in the
benign of a separate benign- tumor (Gleason score 9) pair
( <1.0% AA conversion). One tumor case (patient 3 in Table
2) for which benign tissue was not available showed
particularly strong COX-2 expression, both by in situ
hybridization (Figure 6G ) and protection assay (not shown).
This tumor, a Gleason score 4+4=8, is the same case as
that described above that showed prominent 15-LOX-2
mRNA expression and 15-HETE formation from exogenous
AA. This tumor made trace amounts of PGE2 and HHT
( <0.5% AA conversion) under our assay conditions. Two
other tumors that formed detectable PGE2 and HHT had
positive COX-2 mRNA, whereas two additional tumors with
COX-2 mRNA expression did not form detectable COX
metabolites. In general, no clear correlation existed between
the presence of mRNA for COX-2 and COX metabolite
formation under assay conditions employed. These results
are summarized in Table 2.
COX-2 Immunostaining and In Situ Hybridization in Benign
and Malignant Prostate in Larger Paraffin Sections from
Whole Mount Prostatectomy Specimens
Strong uniform COX-2 immunostaining was seen in all
control sections of ejaculatory duct (Figure 7A ), which was
confirmed by in situ hybridization (Figure 7B ). In addition, 44
of the radical prostatectomy sections studied by immunohis-
tochemistry included cross sections of ejaculatory duct, and
positive COX-2 immunostaining, was seen in these struc-
tures in all cases, with extensive moderate or diffuse strong
staining in 89% and less extensive focal staining of epithelial
cells of the duct seen in the other 11%. Positive seminal
vesicle immunostaining was noted in all eight of the eight
cases in which the base of the seminal vesicles were included
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in immunostained sections (Figure 7C ). Seminal vesicle
COX-2 expression was also noted by in situ hybridization
(Figure 7D ). In contrast, examination of benign prostate
glands and prostate tumor epithelial immunostaining sup-
ported our observations on mRNA analysis in snap- frozen
tissues described above. In 39 of the 87 cases (45%), there
was no detectable COX-2 immunostaining in either benign or
malignant prostate. Twenty- two of these 39 had ejaculatory
duct portions, which were all positive, serving as a positive
internal control and demonstrating the ability of the assay to
detect COX-2 protein when present. In those cases in which
even rare COX-2 immunostaining was noted in either benign
or tumor, the extent of immunostaining was essentially equal
in benign and tumor in 17 (20% of total cases), greater in
benign than tumor in 17 (20%), and greater in tumor than
benign in the same patient in 14 (16%). COX-2 immunos-
taining in benign glands was often noted in central zone
glands (based on relationship to ejaculatory ducts toward
prostate base and characteristic gland morphology [5]
(Figure 7E ). However, focal staining was also noted in
benign peripheral zone glands, with or without atrophy, and
transition zone glands, variably affected by benign prostatic
hyperplasia (not shown). However, most benign prostate
portions were negative as indicated above or showed only
rare weak to moderate immunostaining, with only 22/87
(25%) benign portions of the specimens showing 2+
immunostaining in glandular epithelium. When present in
tumor, COX-2 immunostaining was also largely focal and
weak to moderate in intensity (compared to intensity in
ejaculatory ducts). Only 22/87 (25%) tumor specimens
showed 2+ immunostaining, which also tended to be focal
and heterogeneous (Figure 7F ). However, in these cases
possible upregulation compared to benign was noted.
Twenty- two tumors showed 2+ COX-2 immunostaining,
and in 12 of those 21 it was of greater extent than the benign
portions. In comparison to 7 benign specimens overall, 10
tumors ( from different patients than those with strong
immunostaining in benign) showed 3+ COX-2 immunos-
taining, and in eight of these cases, it was more extensive
than expression in benign portions. Prior anti -androgen
treatment did not appear to cause any discernible difference
in immunostaining in benign or tumor epithelium. Considering
Figure 8. COX-2 immunostaining scores for paired benign and tumor from individual patients by Gleason grade. (A ) Gleason score 2+3 or 3+2=5 tumors; (B )
Gleason score 3+3=6 tumors; (C ) Gleason score 3+4 or 4+3=7 tumors; (D ) Gleason score 4+4=8 and 4+5 or 5+4=9 tumors. Only cases with COX -2
immunostaining in either benign or tumor or both are shown. Cases with no staining in either not illustrated. Increased tumor immunostaining compared to benign
was noted only for high - grade (Gleason score 8 or 9 ) tumors (P< .05 ).
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all cases, no increase inCOX-2 immunostainingwas noted in
tumor versus benign (P=.96). However, when separated into
groups of well -established prognostic difference depending
on grade (Gleason score 5 to 6, 7, 8 to 9) [20], there was a
significant difference in trends for COX-2 expression in tumor
versus benign (P<.001). Likely reflecting the presence of
COX-2 in some benign specimens and lack of marked
upregulation in lower grade tumors, COX-2 expression was
actually significantly decreased in tumor versus benign for
those specimens from patients with Gleason score 5 or 6
tumors (P=.03) (Figure 8 ). There was no difference in
Gleason score 7 samples (P=.48) (Figure 8 ), whereas there
was increased COX-2 expression in tumor versus benign for
specimens from patients with high-grade (Gleason score 8
or 9) tumors (P=.02). (Figure 7,G andH; Figure 8 ). Possible
correlation with grade was also noted in individual cases with
multiple tumors. For example, in one case, a Gleason score 5
tumor in the transition zone was negative (Figure 7I ),
whereas foci of HGPIN and high-grade (Gleason score 9)
tumor in the peripheral zone of the same specimen were
strongly COX-2 immunopositive (Figure 7J ). Hence, the
immunostaining studies employing larger portions of benign
and tumor from individual patients support, but extend the
findings in smaller snap- frozen tissues. Considering all
cases, increased COX-2 expression in tumor versus benign
is not a uniform or common property of prostate cancer. A
small minority may show upregulation of COX-2 by message
and protein analysis, and this appears to be a property of
high-grade tumors.
Discussion
Alterations in expression and activity of AA metabolizing
enzymes may be fundamentally important in the develop-
ment and/or progression of Pca. These enzymes or the
receptors for their products also represent attractive targets
for existing or potential future pharmacologic agents.
Although data from cell lines suggests possible roles for
LOXs and COX-2 in regulating neoplastic prostate cell
growth, very little information exists regarding these path-
ways in prostate tissues. Utilizing snap- frozen prostate
tissues, we have demonstrated that benign prostate char-
acteristically synthesizes 15-HETE from exogenous AA.
Almost all of the examined benign samples made 15-HETE,
and 15-HETE was the major AA metabolite formed. The
enzymatic properties of this 15-LOX activity, including
specific oxygenation at the 15-carbon without appreciable
simultaneous formation of 12-HETE, are characteristic of
15-LOX-2 versus the 15-LOX-1 typical of peripheral blood
leukocytes [23,24]. Furthermore, by immunohistochemistry
15-LOX-2 is expressed in differentiated secretory cells of
benign prostate glands [5], and in the current study, 15-
LOX-2 mRNA was detected in the majority of benign
prostate samples.
The results of the current study substantially extend
previous observations of reduced 15-LOX-2 immunostain-
ing in PCa versus benign prostate [5,6 ], as not only 15-
HETE formation but also 15-LOX-2 mRNA was significantly
reduced in snap- frozen PCa versus benign prostate
peripheral zone. Mechanisms regulating 15-LOX-2 expres-
sion and activity have yet to be reported. Other LOXs are
regulated in a complex manner, including at the transcrip-
tional, pretranslational, translational, and posttranslational
level [25,26]. Our results would indicate that reduction or
loss of 15-LOX-2 in Pca occurs at least in substantial part at
the transcriptional level. The expression of 15-LOX-2 in
prostate and other androgen-regulated tissues, such as
sebaceous glands [27], suggests possible hormonal mod-
ulation of expression. In addition, we have recently observed
in cell strains established from primary prostate tissues that
15-LOX-2 expression is reduced by epidermal growth factor
and transforming growth factor - (Shappell, S.B., Peehl,
D.M., unpublished observations). As these growth factors
and/or their receptors are altered in Pca [14], these
observations suggest possible mechanisms underlying
reduced 15-LOX-2 expression in Pca. The function of 15-
LOX-2 derived 15-HETE in benign prostate and the
mechanism whereby its reduction contributes to PCa remain
to be more fully determined. We have recently shown that
15-HETE activates peroxisome proliferator activated recep-
tor  (PPAR ) and inhibits proliferation in PC-3 PCa cells
[28]. Hence, reduced 15-LOX-2 may contribute to PCa
development or progression by altered expression of
PPAR - regulated genes.
Kelavkar et al. [29 ] recently observed increased 15-
LOX-1 immunostaining in PCa, with possible correlation with
tumor grade and p53 accumulation. As benign prostate
expresses such an abundant 15-LOX activity (15-LOX-2),
it is crucial to compare any 15-LOX activity in malignant
tissues to benign tissues in the same patient. In the current
study, we did observe 15-HETE formation by a minority of
tumors. 15-HETE formation in six admixed benign and
tumor tissues may represent the contribution of benign
glands or subtotal loss of activity in cancer portions. 15-
HETE formation was detected in 1 of 4 pure tumors without
benign counterparts and 5 of 14 tumors in benign- tumor
pairs. Hence, overall 6 of 18 pure tumors made 15-HETE.
Whether this was due to 15-LOX-1 or 15-LOX-2 was not
specifically addressed, as we did not examine 15-LOX-1
expression in the current series. However, as in benign
samples, the product profiles in tumors are more consistent
with 15-LOX-2, and 15-LOX-2 mRNA was detected in at
least some such tumors (Figure 2 ), including very strongly in
a high-grade tumor that made prominent 15-HETE. If
reduced 15-LOX-2 is characteristic of Pca and if some
such tumors also upregulate 15-LOX-1, it will be important
to determine what pathways may be regulated by 15-LOX
activity or AA-derived 15-HETE and linoleic acid–derived
13-hydroxyoctadecadienoic acid (13-HODE) in benign and
malignant prostate cells. The formation of a single product by
15-LOX-2 is more in keeping with a postulated ligand
function [28,30], whereas the ability of 15-LOX-1 to
catalyze mixed oxygenation of phospholipids esterified in
membranes has led to a speculated function in enzymatic
lipid peroxidation in cell and membrane restructuring [30].
What such a function would be in malignant cells remains to
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be established. 15-HETE or 13-HODE formed in benign and
malignant cells could exert different functions, possibly
depending on what other changes have occurred in tumor
cells or in the tumor microenvironment.
Recent studies in Pca cell lines indicated a possible
contribution of 5-LOX and 5-HETE to cancer cell growth.
Low levels of 5-HETE production were detected in PC-3
cells exposed to exogenous AA, which was inhibited by 5-
LOX inhibitors. Exogenous AA stimulated cell growth, which
was also blocked by 5-LOX inhibitors [9 ]. Subsequent
studies have demonstrated detection of 5-LOX and 5-LOX
activating protein (FLAP) in Pca cell lines by PCR and
inhibition of proliferation and induction of apoptosis with
selective 5-LOX and FLAP inhibitors [10,11]. To our
knowledge, however, 5-LOX mRNA, protein, or activity
have not been reported in actual Pca tissues. In our current
study, only trace levels of 5-HETE were detected in
occasional benign and tumor samples, and increased 5-
LOX activity was not detected as a characteristic alteration in
Pca versus benign prostate.
Utilizing RT-PCR techniques, Gao et al. [7 ] reported that
12-LOX mRNA was elevated in 46 of 122 (38%) prostate
tumor samples compared to normal tissue from the same
patient. 12-LOX mRNA was more likely to be elevated in
tumor versus control tissue in patients with extracapsular
extension (T3), positive lymph nodes, higher grade lesions
(Gleason score 8), and positive surgical margins [7].
Substantial in vitro data suggests that 12-HETE in cell lines
may function in tumor cell invasion and metastasis [31–33].
Data in cell lines and nudemice suggests that 12-HETEmay
contribute to tumor growth and angiogenesis [8 ]. Although
mRNA data in actual prostate tissues is supported by in situ
hybridization studies [7], to our knowledge no data on 12-
LOX protein or enzyme activity have been published in
prostate tissues. In our study, increased 12-HETE formation
was not a detectable alteration in Pca under usual assay
conditions. With a more sensitive assay, trace 12-HETE was
detected in occasional benign and tumor tissues (which
included a number of high-grade tumors), with no discern-
ible alteration in Pca versus benign. Whether levels of 5-
LOX and 12-LOX too low to lead to detectable catalytic
activity in our assays may be expressed in high-grade Pcas
in a manner sufficient to contribute to tumor growth, invasion,
or angiogenesis remains to be demonstrated.
The role for altered COX-2 in human carcinoma has been
most supported by studies in colon cancer, including
epidemiologic studies showing reduced colon cancer inci-
dence and mortality with NSAIDs capable of inhibiting COX-
2 [34–36]. Data exist indicating COX-2 upregulation in
carcinomas of the colon [37–39], stomach [40], lung [41],
breast [42], and urinary bladder [16,43]. The mechanisms
by which COX-2 derived PGs or other AA metabolites might
contribute to carcinoma development or progression are not
precisely defined, but potentially include protection against
apoptosis [44] and contribution to tumor angiogenesis [45–
47]. Few data exist on COX-2 expression in benign and
malignant prostate, but recent studies have begun attempt-
ing to address this issue. COX-2 mRNA has been reported
in Pca cell lines [12,13]. A study in the LNCaP PCa cell line
showed induction of apoptosis with high concentrations of a
selective COX-2 inhibitor, although actual inhibition of
enzyme activity was not demonstrated [13].
It is crucial to validate pathways in cell lines with
expression patterns in benign and tumor tissues. Gupta et
al. [48] reported possible COX-2 mRNA upregulation in
snap- frozenmalignant versus benign prostate from the same
patients utilizing RT-PCR. Yoshimura et al. [49] recently
reported COX-2 expression in prostate tumor tissues more
often than in benign samples by RT-PCR. However, such
assays are not quantitative and comparisons were not made
between benign and tumor in the same patient [49]. In our
study, increased COX-2 was not a characteristic alteration in
Pca by nuclease protection assays and in situ hybridization.
Differences between our results for COX-2 mRNA in pairs of
benign and malignant prostate from the same radical
prostatectomies and those recently published by Gupta et
al. [48] are likely due at least in part to differences in
methodology employed. Although less sensitive than RT-
PCR, nuclease protection assays are more sensitive than
Northern blots and are quantitative.We only detectedCOX-2
mRNA utilizing this technique in approximately half of the
samples analyzed (benign or malignant). However, in those
pairs of benign and tumor in which COX-2 was detected,
increased COX-2 was not a common or uniform alteration in
PCa. When mRNA expression is potentially limited to a
fraction of the cell population, in situ hybridization may be
more sensitive than nuclease protection assay. By in situ
hybridization in snap- frozen core sections, we observed that
COX-2 is often expressed in benign prostate glands andmay
not be altered or may actually be decreased in tumor
compared to benign, observations supported by immunos-
taining in a larger number of cases with more substantial
portions of benign and tumor examined in each case.
Previous COX-2 immunostaining studies in prostate
cancer [48,49] have not correlated results with immunos-
taining in structures known to express COX-2 or with more
specific in situ hybridization studies [16]. COX-2 is known to
be expressed in the terminal vas deferens [17]. A large
number of the cases in our study included the segment of the
ejaculatory duct located immediately after the terminal vas
deferens and seminal vesicle join to form the ejaculatory
duct, and all these structures have a common embryologic
origin from theWolffian duct. Strong uniform immunostaining
for COX-2 was seen in the ejaculatory ducts, which was
confirmed by in situ hybridization employing riboprobes
based on sequences unique to COX-2 versus COX-1 [16].
These results formed the basis for validating the immunos-
taining results in benign and malignant prostate.
In our study, results of immunostaining agreed in general
with those of protection assays and in situs in snap- frozen
tissues, in that COX-2 was not detected in benign or tumor
portions of approximately half of the cases. In cases in which
COX-2 was detected, it was more often reduced in tumor
compared to benign, which was significant in Gleason score
5 and 6 tumors. It is unlikely that reduced expression of
COX-2 actually contributes to tumor development or
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progression in these tumors. The results more likely are due
to a combination of the occasional expression of COX-2 in
benign prostate, the methods employed for performing the
semiquantitative assessment of COX-2 immunostaining,
and the fact that COX-2 is not highly expressed in these
tumors. Interestingly, in a recent in vitro study, basal levels of
COX-2 mRNA and protein were higher in cells (PrEC)
established from benign prostate than in the prostate cancer
cell lines PC3, DU145, and LNCaP [50]. In benign prostate
portions examined in our study, COX-2 immunostaining was
often noted in glands of the central zone. In the small
proportion of tumors that strongly express COX-2, a more
rigid comparison to peripheral zone glands and high-grade
prostatic intraepithelial neoplasia from which such tumors
likely arise may be warranted to more definitively demon-
strate upregulation of COX-2 in tumor versus benign. In the
snap- frozen cores, no precise correlation existed between
the presence of mRNA for COX-2 and COX metabolite
formation under assay conditions employed. Whether COX-
1 contributes to product formation in some cases is not
known, but likely. Regardless, message and immunohisto-
chemistry analysis would indicate that increased COX-2 in
tumor versus benign is not a typical change in prostate
cancer. These results challenge the emerging view that
COX-2 upregulation is a common manifestation of malig-
nancy ( in the prostate), and indicate the need for more rigid
validation of assays employed in the growing number of
reports emerging in this field.
A statistically significant increase in COX-2 immunostain-
ing was observed in high-grade tumors (Gleason score8).
The lack of a consistent alteration in COX-2 expression in all
Pcas does not mean that upregulation is not important in
those specific cases in which COX-2 is elevated in tumor.
This subset of patients with high-grade Pca often have
tumors extending beyond the prostate on clinical staging at
presentation or such patients are at marked risk for systemic
progression following definitive treatment. The extremely
poor prognosis in these patients [20]mandates the discovery
of more effective pharmacologic treatments. The possible
correlation of increased COX-2 with high tumor grade is
further important, as investigators are beginning to use
human prostate cancer cell lines in investigations of COX-2
inhibitors in Pca [51]. As these cell lines are established from
advanced high-grade tumors, our observations support that
these may be a valid model for these specific tumors. As
such, COX-2 inhibitors warrant further investigation for this
patient subset. Our data herein showing the common
reduction of 15-LOX-2 in Pca and recent data showing 15-
HETE activation of PPAR in prostate cell lines [28] supports
the further investigation of synthetic PPAR agonists to treat
Pca patients, as recently reported for advanced Pca [52], as
well as other possible functions of 15-LOX-2 in prostate.
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